32470-52-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(PIPERIDIN-4-YLMETHYL)PIPERIDINE serves as a crucial building block in the development of new pharmaceuticals. Its distinctive structure allows for the creation of complex organic molecules with potential therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(PIPERIDIN-4-YLMETHYL)PIPERIDINE is utilized for its reactivity and structural attributes, which can be leveraged to design and synthesize novel compounds with potential medicinal applications.
Used as a Reagent in Chemical Reactions:
1-(PIPERIDIN-4-YLMETHYL)PIPERIDINE also functions as a reagent in various chemical reactions, facilitating the synthesis of a wide range of organic molecules.
Used as a Starting Material for Organic Synthesis:
Furthermore, it acts as a starting material for the preparation of complex organic molecules, contributing to the advancement of organic chemistry and the development of new chemical entities.

InChI:InChI=1/C11H22N2/c1-2-8-13(9-3-1)10-11-4-6-12-7-5-11/h11-12H,1-10H2

Upstream product

• 34490-39-6 4-((piperidin-1-yl)methyl)pyridine 
• 1192124-16-5 benzyl 4-(piperidin-1-ylmethyl)piperidine-1-carboxylate 
• 110-89-4 piperidine 
• 893086-61-8 4-piperidin-1-ylmethyl-piperidine-1-carboxylic acid (4-bromo-phenyl)amide 
• 757949-38-5 4-(piperidine-1-carbonyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 63214-58-4 piperidin-4-yl-piperidin-1-yl-methanone 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 6457-49-4 4-piperidinemethanol 
• 184968-88-5 1,1-dimethylethyl 4-(1-piperidinylmethyl)-1-piperidinecarboxylate 

Downstream Products

• 486436-41-3 1-methyl-2-[4-(piperidin-1-yl)methyl-piperidinocarbonyl]-4-(4'-trifluoromethylbiphenyl-2-carbonylamino)-pyrrole 
• 893086-61-8 4-piperidin-1-ylmethyl-piperidine-1-carboxylic acid (4-bromo-phenyl)amide 
• 1401619-11-1 (1-(4-chlorobenzyl)-1H-indol-2-yl)(4-(piperidin-1-ylmethyl)piperidin-1-yl)methanone 
• 81310-65-8 1-[(E)-2-(3-Bromo-phenyl)-propenyl]-4-piperidin-1-ylmethyl-piperidine 
• 1401618-65-2 (1-(4-fluorobenzyl)-1H-indol-2-yl)(4-(piperidin-1-ylmethyl)piperidin-1-yl)methanone 

Relevant academic research and scientific papers

Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety

We herein report the design and synthesis of benzothiazinones containing a piperidine moiety as new antitubercular agents based on the structure feature of IMB-ZR-1 discovered in our lab. Some of them were found to have good in vitro activity (MIC 1 μg/

Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor

α7 nicotinic acetylcholine receptor agonists are promising therapeutic candidates for the treatment of cognitive impairment. As a follow up of our internal medicinal chemistry program we investigated a novel series of α7 nAChR agonists. Starting from molecular docking studies on two series of molecules recently developed in our laboratories, an alternative scaffold was designed attempting to combine the optimal features of these previously identified urea and pyrazole compounds. Based on our previous SAR knowledge and on predicted drug-like properties, a small library was synthesized in parallel manner, affording compounds with excellent α7 nAChR activity, selectivity and preliminary ADME profile.

MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF

Compounds with α7 nicotinic acetylcholine receptor (α7 nAChR) agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric diseases.

SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS

This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal.

MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF

Compounds with α7 nicotinic acetylcholine receptor (α7 nAChR) agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric diseases.

SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS

Compounds within the genus represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein: T is substituted phenyl or substituted pyridyl; R is H, methyl, ethyl, -CH2CN, -CH2C(O)NH2, -(CH2)3SO3H, -CH2C(O)NHCH3, -CH2C(O)NHOH, -CH2C(O)NHOCH3, -CH2C(O)NHCH2CN, -CH2F, -CH2C(O)NHCH2SO3H, (a), (b), (c), (d) or (e); R is methyl or ethyl; and Z is substituted piperidinyl.

New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture

The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1, R2, R3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors

The NK1 and NK2 receptor activity of a series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4(Z)- (methoxyimino)pentyl-1-piperidines was evaluated. Compounds 11d, 11e, 11f, 12a, and 12k were found to be our most potent inhibitors.